Author(s):
Hemraj Singh Rajput, Shivangi Solanki, Saurabh Jain, Sneha Verma, Lisa Patel, Meet Ramani, Rajesh Hadia, Jitendra Lakhani
Email(s):
docrajesh.hadia@gmail.com
DOI:
10.52711/0974-360X.2025.00837 
Address:
Hemraj Singh Rajput1, Shivangi Solanki2, Saurabh Jain3, Sneha Verma1, Lisa Patel1, Meet Ramani1, Rajesh Hadia1*, Jitendra Lakhani3
1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara - 391760, Gujarat, India.
2Department of Nephrology, SBKS Medical Institute and Research Center, Sumandeep Vidyapeeth Deemed to be University, Vadodara - 391760, Gujarat, India.
3Department of General Medicine, SBKS Medical Institute and Research Center, Sumandeep Vidyapeeth Deemed to be University, Vadodara - 391760, Gujarat, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
End-Stage Renal Disease (ESRD) often leads to anemia, contributing to a spectrum of complications, from lethargy to heightened vulnerability to infections. This study explores the potential of correcting anemia and reducing reliance on blood transfusions in ESRD patients with the administration of subcutaneous erythropoietin (4000 IU thrice a week). The primary objectives were to evaluate the effectiveness, side-effects, and the diminished need for blood transfusions following erythropoietin (EPO) administration in subjects undergoing Maintenance hemodialysis for ESRD. Sixty subjects aged >18 years, receiving EPO, were enrolled in this study for a duration of 6 months. Primary end points, including Hemoglobin (Hb), Serum Ferritin, Total Iron Binding Capacity (TIBC), and Serum Iron, along with side-effects of EPOETIN ALPHA, were assessed over a 12week epoetin therapy period. After 12 weeks, notable improvements were observed, including a 13.86% increase in Hb, a 32.84% increase in serum iron, a 5.67% decrease in TIBC, and a 3.93% decrease in serum ferritin. Mild side-effects were encountered by 28 out of 60 subjects. A substantial 75% reduction in blood transfusion frequency was noted. The study concludes that EPO demonstrated efficacy with manageable adverse reactions, significantly reducing the need for blood transfusions. Thus, suggesting a positive impact on the anemic status of subjects undergoing maintenance hemodialysis for ESRD.
Cite this article:
Hemraj Singh Rajput, Shivangi Solanki, Saurabh Jain, Sneha Verma, Lisa Patel, Meet Ramani, Rajesh Hadia, Jitendra Lakhani. Assessing the Effectiveness and Safety of Erythropoietin in Chronic Kidney Disease: An Observational Study. Research Journal Pharmacy and Technology. 2025;18(12):5807-3. doi: 10.52711/0974-360X.2025.00837
Cite(Electronic):
Hemraj Singh Rajput, Shivangi Solanki, Saurabh Jain, Sneha Verma, Lisa Patel, Meet Ramani, Rajesh Hadia, Jitendra Lakhani. Assessing the Effectiveness and Safety of Erythropoietin in Chronic Kidney Disease: An Observational Study. Research Journal Pharmacy and Technology. 2025;18(12):5807-3. doi: 10.52711/0974-360X.2025.00837 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-27
REFERENCES:
1. Senthilkumar S, Dhivya K. Prognostic Potential of Serum Biomarkers as Predictors for Cardiovascular Complications and Disease Progression in Chronic Kidney Disease Patients. Research J. Pharm. and Tech. 2016; 9(3): 227-234. doi: 10.5958/0974-360X.2016. 00041.X
2. Achsa Thomas, Julia S. Jacob, Merin Abraham, Blessy M. Thomas, Purnima Ashok. Assessment of Acute complications and Quality of Life in Hemodialysis patients with chronic kidney disease. Research Journal of Pharmacy and Technology. 2021; 14(5): 2671-5. doi: 10.52711/0974-360X.2021.00471.
3. Asima Nasreen Borah, Kanchan Anand, Sameer Shrivastava, Nidhia, Aakriti Garg, Mohd Ashif Khan. Effect of exercise on quality of life of patients with chronic kidney disease. Research Journal of Pharmacy and Technology. 2023; 16(7): 3195-0. doi: 10.52711/0974-360X.2023.00525.
4. Gangadhar Naik, Virendra Ligade, Shankar Prasad, Vasudeva Guddattu, Sreedhar D. Healthcare schemes for Hemodialysis patients in India: An Overview and Utilization in selected hospitals. Research Journal of Pharmacy and Technology. 2022; 15(10): 4382-8. doi: 10.52711/0974-360X.2022.00735.
5. Christina Pothen, Bibin Baby, Anusree Ashokan, Chinju Chacko, Pradeep Shenoy, Nandakumar UP. Drug Usage Pattern in Chronic Kidney Disease patients undergoing maintenance Hemodialysis. Research J. Pharm. and Tech. 2019; 12(10): 5024-5028. doi: 10.5958/0974-360X.2019.00872.2
6. Ajay K. Singh KC, Vlado Perkovic, Scott Solomon, Vivekanand Jha, Kirsten L. Johansen, Renato D. Lopes, Iain C. Macdougall, Gregorio T. Obrador, Sushrut S. Waikar, Christoph Wanner, David C. Wheeler, et al., for the ASCEND-D Study Group*. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. New England Journal of Medicine. 2021; 385(25): 2325–35. doi.org/10.1056/nejmoa2113379.
7. Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. American Journal of Kidney Diseases. 2018; 71(3): 423-35. doi.org/10.1053/j.ajkd.2017.09.026.
8. Mutaz Sabah A, Khdhair Abbas K, Shaymaa Mohammed Salih. The Relationship between Serum Level of Ferritin and Cardiac Troponin T (cTnT) in Children with Major Beta-Thalassemia. Research J. Pharm. and Tech. 2019; 12(4): 1713-1716. doi: 10.5958/0974-360X.2019.00285.3
9. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Maintenance hemodialysis Patients. 2006; 17(4): 1181-91. doi.org/10.1681/asn.2005090997.
10. Ramy M. Hanna ESKK-Z. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Advances in Therapy. 2021; 38: 52–75. doi.org/10.1007/s12325-020-01524-6.
11. Stivelman JC. Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn). Seminars in Dialysis. 2017; 30(2): 124-48. doi.org/10.1111/sdi.12569.
12. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization. 2018; 96(6): 414-22d. doi.org/10.2471%2FBLT.17.206441.
13. Warady MAABA. Anemia in chronic kidney disease. Pediatric Nephrology. 2017; 33(2): 227–38. doi.org/10.1007/s00467-017-3663-y.
14. Maram Jbaily, Firas Hussein, Nisrin Kaddar. The Role of Serum Lactate Dehydrogenase in Etiological Diagnosis of Macrocytic Anemia. Research Journal of Pharmacy and Technology. 2022; 15(12): 5421-4. doi: 10.52711/0974-360X.2022.00913.
15. Enas Abdul Kareem Jabbar, Afrah Abid Maktoof, Jamela Jouda. Evaluation of Metal levels and Physiological parameters in Sickle cell anemia and their comparison with Iron deficiency anemia. Research J. Pharm. and Tech. 2020; 13(10): 4655-4660. doi: 10.5958/0974-360X.2020.00819.7
16. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet (London, England). 2017; 389(10075): 1238-52. doi.org/10.1016/s0140-6736(16)32064-5.
17. K. Sai Girisha, Mohan Ram. A Prospective Study on Efficacy of Mircera for Treating Anemia Associated with Chronic Kidney Disease. Research J. Pharm. and Tech. 2017; 10(11): 3807-3809. doi: 10.5958/0974-360X.2017.00691.6
18. Srinivasan R, Fredy IC, Chandrashekar S, Saravanan J, Mohanta GP, Manna PK. Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients. Biomedicine and Pharmacotherapy. 2016; 82: 44-8. doi.org/10.1016/j.biopha.2016.04.041.
19. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Annals of internal medicine. 2010; 153(1): 23-33. doi.org/10.7326/0003-4819-153-1-201007060-00252.
20. Ghassan F. Mohammmed, Safaa M. Sultan, Yaman Q. Sadullah. The relationship between Creatinine and patients with Renal Failure associated with anemia. Research J. Pharm. and Tech. 2020; 13(4): 1633-1635. doi: 10.5958/0974-360X.2020.00296.6.
21. Johnson DW. Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes. Evidence-Based Medicine. 2016; 21(5): 178. doi.org/10.1136/ebmed-2016-110418
22. Kuragano T, Matsumura O, Matsuda A, Inoue T, Itakura I, Nakanishi T. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney International. 2014; 86(4): 845-54. doi.org/10.1038/ki.2014.114.
23. Kawano T, Kuji T, Fujikawa T, Ueda E, Shino S, Yamaguchi S, Ohnishi T, Tamura K, Hirawa N and Toya Y. Timing-adjusted iron dosing enhances erythropoiesis-stimulating agent-induced erythropoiesis response and iron utilization. Renal Replacement Therapy. 2017;3. doi.org/10.1186/s41100-017-0103-1.
24. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis‐stimulating agents for anaemia in adults with chronic kidney disease: a network meta‐analysis. Cochrane Database of Systematic Reviews. 2014(12). doi.org/10.1002/14651858.cd010590.pub2.
25. Nagisetty S, NSJ, TMT, MP. Efficacy And Safety Profile of Erythropoietin in Chronic Kidney Disease Patients of Vizianagaram, Andhra Pradesh. International Journal of Health and Clinical Research. 2022; 5(3): 209–12.